Will FTC Challenge Product Switching In Obama Administration?
Lawyers are wary that the Federal Trade Commission may take a more aggressive stance toward pharmaceutical industry practices in the Obama administration
You may also be interested in...
New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.
Legislative effort on settlements kicks into high gear with Senate markup and a new bill that would rescind generic exclusivity in some cases.
The companies decide it is not worth the cost and time to battle the FTC in court; the derailed deal may signal tougher times for pharma mergers.